
Larimar Therapeutics, Inc. Common Stock
LRMR
LRMR: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
moreShow LRMR Financials
Recent trades of LRMR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LRMR's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on LRMR's company Twitter account
Number of mentions of LRMR in WallStreetBets Daily Discussion
Recent insights relating to LRMR
Recent picks made for LRMR stock on CNBC
ETFs with the largest estimated holdings in LRMR
Flights by private jets registered to LRMR